Author Archives: Alice Melão, MSc

Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections

Aridis Pharmaceuticals has enrolled the first healthy participant in its Phase 1/2a clinical trial to evaluate the antibacterial potential of its investigational candidate, AR-501 (gallium citrate), against chronic lung infections in patients with cystic fibrosis (CF). The study (NCT03669614) is expected to enroll approximately 48 healthy adult volunteers and…

GEn1E to Explore MUC1-ED to Prevent P. Aeruginosa Infections in CF

GEn1E Lifesciences has added to its development pipeline an investigational non-antibiotic, antibacterial agent for treatment of Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). The company established an exclusive option agreement with the University of Maryland, Baltimore (UMB) to license patent rights over the MUC1-ecto-domain (MUC1-ED) compound, currently…

Majority of CF Patients in Small Study Treated with Antibiotics at Levels Too Low to Fight Lung Infections

Ten of 19 cystic fibrosis (CF) patients given antibiotics to manage pulmonary exacerbations did not achieve high enough blood concentrations of the antibiotic to sustain a therapeutic effect, results of single-site study show. This failure may be contributing to the development of antibiotic-resistant pulmonary infections, and to a worsening of…